LSCIBP
LSCIBC
Overview
LSCIBC
131
Components
$1.6B
Median Mkt Cap
(as of 6/30/2026)
(as of 6/30/2026)
Equal
Weighting
Semi-Annual
Reconstitution
LSCIBC Index Performance
Past performance is not indicative of future results. One cannot invest directly in an index. Source: LifeSci Index Partners / Indxx, Inc.
What Is LSCIBC?
The LifeSci Biotechnology Clinical Trials Index tracks U.S.-listed pure biotechnology companies whose lead drug candidate is currently in Phase 1, 2, or 3 human clinical trials. With 131 components at equal weight, LSCIBC captures the high-growth, high-innovation segment of the biotech pipeline.
When to Use LSCIBC
LSCIBC is designed for investors seeking exposure to clinical-stage biotechnology — companies at the frontier of drug development with significant upside potential from trial data readouts, regulatory milestones, and M&A activity.
Representative Holdings as of 6/30/2026
| Ticker | Company | Stage |
|---|---|---|
| Late-Stage (Phase 3) | ||
| RVMD | Revolution Medicines | Phase 3 |
| SMMT | Summit Therapeutics | Phase 3 |
| AMLX | Amylyx Pharmaceuticals | Phase 3 |
| Mid-Stage (Phase 2) | ||
| TYRA | Tyra Biosciences | Phase 2 |
| ANAB | AnaptysBio | Phase 2 |
| ALLO | Allogene Therapeutics | Phase 2 |
| Early-Stage (Phase 1) | ||
| RCKT | Rocket Pharmaceuticals | Phase 1 |
| ASMB | Assembly Biosciences | Phase 1 |
| JANX | Janux Therapeutics | Phase 1 |